I believe GC would want to keep most of the cash r
Post# of 30029
Posted On: 12/04/2014 7:52:17 PM
Re: Anaconda83 #12437
I believe GC would want to keep most of the cash received from a lympro/diagnostics sale to fund ambs' main business, just my opinion.
I'm curious what becomes of the spun-off diagnostics company. Will it be left with a small amount of cash and some small portion of future lympro revenues? Will they be partially owned by another company? If they have no revenue for now and minimal cash -- just enough to operate until lympro revenues start paying the bills - then will the dx company qualify to remain on nasdaq? I'd say Gerald would want to keep the dx company's sharecount low if listing it on a national exchange is a priority. So maybe 1 for 10 stock distribution or greater since the fewer outstanding shares the better for the new dx company, imo.
I'm curious what becomes of the spun-off diagnostics company. Will it be left with a small amount of cash and some small portion of future lympro revenues? Will they be partially owned by another company? If they have no revenue for now and minimal cash -- just enough to operate until lympro revenues start paying the bills - then will the dx company qualify to remain on nasdaq? I'd say Gerald would want to keep the dx company's sharecount low if listing it on a national exchange is a priority. So maybe 1 for 10 stock distribution or greater since the fewer outstanding shares the better for the new dx company, imo.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼